Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study).
Chihara Y, Yamada T, Uchino J, Tamiya N, Kaneko Y, Kishimoto J, Takayama K. Chihara Y, et al. Among authors: tamiya n. Transl Lung Cancer Res. 2019 Dec;8(6):1086-1090. doi: 10.21037/tlcr.2019.11.19. Transl Lung Cancer Res. 2019. PMID: 32010586 Free PMC article.
[Two cases of complex sleep apnea syndrome].
Yamada T, Arimoto T, Koyama Y, Masui A, Tamiya N, Hosogi S, Hiramatu A, Nakanishi M, Kohno Y, Ueda M, Iwasaki Y, Marunaka Y. Yamada T, et al. Among authors: tamiya n. Nihon Kokyuki Gakkai Zasshi. 2009 Sep;47(9):793-7. Nihon Kokyuki Gakkai Zasshi. 2009. PMID: 19827583 Japanese.
Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment.
Uchino J, Nakao A, Tamiya N, Kaneko Y, Yamada T, Yoshimura K, Fujita M, Takayama K. Uchino J, et al. Among authors: tamiya n. Medicine (Baltimore). 2018 Jun;97(23):e11081. doi: 10.1097/MD.0000000000011081. Medicine (Baltimore). 2018. PMID: 29879078 Free PMC article. Clinical Trial.
Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study).
Hiranuma O, Uchino J, Yamada T, Chihara Y, Tamiya N, Kaneko Y, Yoshimura K, Takayama K. Hiranuma O, et al. Among authors: tamiya n. Clin Lung Cancer. 2019 May;20(3):e402-e406. doi: 10.1016/j.cllc.2019.02.016. Epub 2019 Feb 27. Clin Lung Cancer. 2019. PMID: 30905617 Free article.
Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report.
Nishioka N, Yamada T, Harita S, Hirai S, Katayama Y, Nakano T, Okura N, Tamiya N, Kaneko Y, Uchino J, Takayama K. Nishioka N, et al. Among authors: tamiya n. Respir Med Case Rep. 2018 Oct 6;25:261-263. doi: 10.1016/j.rmcr.2018.10.004. eCollection 2018. Respir Med Case Rep. 2018. PMID: 30310765 Free PMC article.
402 results